Antisense DNAs as targeted therapeutics for cancer: no longer a dream.
Progress in antisense technology has been rapid, and the traditional antisense inhibition of gene expression has now been viewed at a genomic scale. This global view has led to a deeper understanding of the mechanism of action, the elimination of non-specific and undesirable side effects and, ultimately, greater efficacy and reduced toxicity for nucleic acid medicines. Several antisense oligonucleotides are in clinical trials; these are well tolerated and have therapeutic potential. Antisense oligonucleotides are promising molecular medicines with potential to treat human cancer in the foreseeable future.
Cellular Biochemistry Section, BRL, CCR, National Cancer Institute, NIH, Bethesda, MD 20892-1750, USA. ChoChung@helix.nih.gov
Yoon S
YS
Cho-Chung
D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D016373:DNA, Antisense / Q000737:chemistry / Q000627:therapeutic use*; D015870:Gene Expression / Q000187:drug effects*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D020319:Oligodeoxyribonucleotides, Antisense / Q000737:chemistry / Q000627:therapeutic use
D016373:DNA, Antisense; D020319:Oligodeoxyribonucleotides, Antisense